CTRI/2009/091/000182Other3 期
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety And Efficacy Study Of Sitaxsentan Sodium In Subjects With Pulmonary Arterial Hypertension. - None
试验速览
- 阶段
- 3 期
- 状态
- Other
- 入组人数
- 183
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Ages Eligible for Study: 16 Years to 80 Years
- •Genders Eligible for Study: Both
- •Accepts Healthy Volunteers: No
- •Current diagnosis of symptomatic pulmonary arterial hypertension (PAH) classified by one of the following: idiopathic arterial hypertension (IPAH), primary pulmonary hypertension (PPH), familial pulmonary arterial hypertension (FPAH) or pulmonary arterial hypertension (PAH) associated with connective tissue diseases. Has WHO functional class III symptoms
排除标准
- •Previous exposure to an endothelin receptor antagonist (ETRA) such as sitaxsentan, bosentan or ambrisentan.
研究者
相似试验
进行中（未招募）
1 期
This is a Phase 3 multi-center, randomized, double-blind, placebo-controlled, parallel group study to investigate the efficacy of 24 weeks of treatment with fostamatinib (R788) vs. placebo in increasing hemoglobin in subjects with warm antibody autoimmune hemolytic anemia (wAIHA) who have failed at least one prior treatment regimen.Warm antibody autoimmune hemolytic anemia (wAIHA)MedDRA version: 20.0Level: LLTClassification code 10003825Term: Autoimmune hemolytic anemiaSystem Organ Class: 100000004851EUCTR2018-004774-97-GBRigel Pharmaceuticals, Inc.90
进行中（未招募）
1 期
Safety and Efficacy of Apremilast in Children 6 through 17 Years with Moderate to Severe Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858Plaque PsoriasisEUCTR2018-002918-12-CZAmgen Inc.230
进行中（未招募）
不适用
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) - BLISS-76Systemic Lupus Erythematosus (SLE)MedDRA version: 8.1Level: LLTClassification code 10042945Term: Systemic lupus erythematosusEUCTR2006-005177-21-ATHuman Genome Sciences, Inc.810
进行中（未招募）
1 期
A Phase 3 Study of Fostamatinib Disodium in the Treatment Immune Thrombocytopenic PurpuraEUCTR2013-005453-76-ATRigel Pharmaceuticals, Inc.75
进行中（未招募）
1 期
Safety and Efficacy of Apremilast in Children 6 through 17 Years with Moderate to Severe Plaque PsoriasisPlaque PsoriasisEUCTR2018-002918-12-HUAmgen Inc.230